BioSpace News Archive

Clinical evidence shows significant patient radiation reduction with CorPath® GRX Vascular Robotic System

EyePoint Pharmaceuticals, Inc., a pharmaceutical company committed to developing and commercializing innovative ophthalmic products, announced the presentation of positive retrospective case study data supporting DEXYCU® 9% for the treatment of post-operative inflammation following ocular surgery.

Amivantamab-treated patients achieved durable remissions in CHRYSALIS study; data will be presented during ASCO Virtual Scientific Program [18-May-2020] RARITAN, N.J. , May 18, 2020 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today results from the Phase 1 CHRYSALIS study ( NCT02609776 ) evaluating amivantamab (JNJ-6372) in

Data from SER-109 Phase 3 study in recurrent C. difficile infection expected mid-2020

Financing Supports Ongoing Phase 1 Trial of SQZ APC Platform in HPV+ Tumors and Advancement of SQZ AAC Platform towards an Investigational New Drug Application

Can-Fite BioPharma Ltd., a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, announced additional findings from its Phase II study of Namodenoson in the treatment of patients with non-alcoholic fatty liver disease with or without non-alcoholic steatohepatitis.

AstraZeneca and Daiichi Sankyo Company, Limited’s ENHERTU® has been granted Breakthrough Therapy Designation in the US for the treatment of patients with metastatic non-small cell lung cancer whose tumors have a HER2 mutation and with disease progression on or after platinum-based therapy.

Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced the management team will present at the upcoming Solebury Trout Virtual Global Healthcare Conference Series. Details are as follows: Date/Time : Tuesday, May 26, 2020 at 12:00 p.m. EDT To access the prese

- Met Primary Endpoint with a Correct Localization Rate of 84.8–87.0% - - 63.9% Change in Disease Management Plan Based on PyL Imaging Results - - Planned NDA Submission On Track for Early Third Quarter 2020 - NEW YORK, May 18, 2020 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative medicines and artificial intelligence to find, fight and follow cancer, today announced that the results from the Phase 3 CONDOR trial evaluating the

The NCCN 2020 Annual Conference providing the latest updates on cancer treatment recommendations was initially postponed due to COVID-19.